Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04093362
Title	Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)
Acronym	FOENIX-CCA3
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Taiho Oncology, Inc.
Indications	intrahepatic cholangiocarcinoma
Therapies	Futibatinib Cisplatin + Gemcitabine
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG